Background {#Sec1}
==========

Gastrointestinal stromal tumor (GIST) is the commonest mesenchymal tumor in alimentary tract representing an annual incidence of 10 cases per million people worldwide \[[@CR1]\]. While this kind of tumor could originate from the interstitial Cajal cells (ICC) throughout the entire alimentary tract, GISTs are mostly found in the stomach (60--70%), small intestine (20--30%) and colorectum (10%) \[[@CR2]\]. Notably, only 1--5% GISTs occurred in the duodenum \[[@CR3]\]. Thus, the research on duodenal GIST was lacking due to its rare incidence.

To date, complete resection without lymph node clearance is the standard curative treatment for primary localized GISTs \[[@CR4], [@CR5]\]. However, the optimal surgical procedure for duodenal GISTs is not well defined due to their complex anatomy around the pancreaticoduodenal region \[[@CR6]--[@CR8]\]. The limited resection (LR) is reported to be a technically feasible and oncologically sound procedure for duodenal GISTs, while the pancreaticoduodenectomy (PD) is also warranted in some cases due to the anatomical considerations of the proximity of critical structures, including the papilla, pancreas and biliary and pancreatic ducts \[[@CR9]--[@CR12]\]. However, the survival impact of surgical procedure on duodenal GISTs still remains controversial \[[@CR6], [@CR13], [@CR14]\].

Thus, the current study aimed to investigate the optimal surgical strategy and prognosis of duodenal GISTs based on the largest sample size so far.

Methods {#Sec2}
=======

Thirty-seven cases of duodenal GISTs which were diagnosed and treated in our center from May 2010 to November 2016, and 263 cases of duodenal GISTs reported in the literature were enrolled into this study. Literature published in English from 1st January 2000 to 1st January 2017 were searched in the database of MEDLINE using the following keywords: (GIST OR gastrointestinal stromal tumor OR gastrointestinal stromal tumour OR GISTs OR gastrointestinal stromal tumors OR gastrointestinal stromal tumours OR extragastrointestinal stromal tumor OR extragastrointestinal stromal tumors OR extragastrointestinal stromal tumour OR extragastrointestinal stromal tumours) AND (duodenum OR duodenal). The research resulted in 101 eligible case reports or series \[[@CR8], [@CR10], [@CR12], [@CR15]--[@CR112]\] including 263 cases of duodenal GISTs. Finally, a total of 300 cases of duodenal GISTs were identified in our study (Additional file [1](#MOESM1){ref-type="media"}). In addition, the clinicopathological features and prognosis of duodenal GISTs were compared with 378 gastric GISTs which were diagnosed and treated from May 2010 to November 2016 in our center. This study was approved by the Ethics Committee of Xijing Hospital, and written informed consents were obtained from the patients.

Clinicopathological factors including age, gender, preoperative symptoms, anatomical location, surgical procedure, resection margin, tumor size, mitotic index, morphology, immunohistochemistry, genomic mutation, National Institutes of Health risk category (NIH), adjuvant therapy and survival data were collected. The GISTs were classified as very low, low, intermediate and high risk following the modified protocol of NIH risk classification reported by Joensuu \[[@CR113]\].

For survival analysis, the exclusion criteria were listed as follows (Both for duodenal and gastric GISTs): 1) accompanied with other malignant tumors or GISTs in other locations; 2) with distant metastasis or tumor rupture; 3) with neoadjuvant therapy; 4) not received R0 resection; 5) without follow-up records. Because of data acquisition, completeness of data is limited. Finally, a total of 202 patients of duodenal GISTs and 253 patients of gastric GISTs were included for survival analysis.

Data were processed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL). Numerical variables were expressed as the mean ± SD unless otherwise stated. Discrete variables were analyzed using the Chi-square test or Fisher's exact test. Risk factors for survival were identified by univariate analysis and Cox proportional hazards regression model was used for multivariate analysis. Evaluation for disease-free survival (DFS) and disease-specific survival (DSS) were obtained by the Kaplan-Meier method and differences between curves were compared using log-rank test. The *P*-values were considered to be statistically significant at the 5% level.

Results {#Sec3}
=======

The clinicopathological characteristics of 300 duodenal GISTs were summarized in Table [1](#Tab1){ref-type="table"}. There were 143 male (49.1%) and 148 female (50.8%). The patient age ranged from 7 to 84 years (mean, 56 years; median, 57 years). The most common symptom was bleeding (128/300, 42.7%) followed by abdominal pain (56/300, 18.7%). Descending portion was the most common site (137/266, 51.5%), followed by horizontal portion (65/266, 24.4%), superior portion (42/266, 15.8%) and ascending portion (22/266, 8.3%). R0 resection was performed for the 91.7% of the patients. There were only 2 patients that underwent R1 or R2 resection. One hundred and ninety-nine (66.3%) patients received LR and 78 (26.0%) patients received PD. The tumors ranged from 0.1 cm to 28 cm (mean: 5.6 cm; median: 4 cm) in maximum diameter. The mitotic index of 59 (24.6%) patients exceeded 5/50 high-power field (HPF). One hundred and twenty-seven patients (49.2%) were classified as high risk by the NIH risk category, and 104 patients (40.3%) were at low risk. A total of 13 (4.3%) patients received neoadjuvant therapy and 37 (12.3%) patients received imatinib therapy after surgery.Table 1Clinicopathological characteristics of 300 cases of duodenal GISTsCharacteristicsParametersAge (∑ = 267)  ≤ 60161 (60.3%)  \> 60106 (39.7%)Gender (∑ = 291) Male143 (49.1%) Female148 (50.8%)Symptoms (∑ = 300) Bleeding or anemia128 (42.7%) Abdominal pain56 (18.7%) Abdominal mass11 (3.7%) Abdominal discomfort11 (3.7%) Anorexia6 (2.0%) Othersa^a^36 (12.0%)Anatomical location (∑ = 266) Superior portion42 (15.8%) Descending portion137 (51.5%) Horizontal portion65 (24.4%) Ascending portion22 (8.3%)Surgical procedure (∑ = 300) Limited resection\*199 (66.3%) Pancreaticoduodenectomy78 (26.0%) Not available13 (4.3%) No surgery10 (3.3%)Resection margin (∑ = 300) R0275 (91.7%) R1/22 (0.7%) Not available/No surgery23 (7.7%)Tumor size (∑ = 277)  ≤ 2 cm34 (12.3%) 2--5 cm135 (48.7%) 5--10 cm73 (26.4%)  \> 10 cm35 (12.6%)Mitotic index (∑ = 240)  ≤ 5181 (75.4%)  \> 559 (24.6%)Morphology (∑ = 160) Spindle148 (92.5%) Epithelioid1 (0.6%) Mixed11 (6.9%)Immunohistochemistry CD117 (∑ = 288)284 (98.6%) DOG-1 (∑ = 41)40 (97.6%) CD34 (∑ = 167)126 (75.4%)Genomic mutation (∑ = 41) KIT31 (75.6%) PDGFRA1 (2.4%) KIT and PDGFRA5 (12.2%) Wild type4 (9.8%)NIH risk category (∑ = 258) Very low25 (9.7%) Low104 (40.3%) Intermediate2 (0.8%) High127 (49.2%)Neoadjuvant therapy (∑ = 300) No287 (95.7%) Yes13 (4.3%)Adjuvant therapy (∑ = 300) No263 (87.7%) Yes37 (12.3%)Follow-up (∑ = 202, month) Mean ± SD39.3 ± 39.4 Median (range)25.0 (13.0, 58.5)Survival rate (∑ = 202) 1−/3−/5−/10-year DFS94.4%/75.2%/64.4%/46.5% 1−/3−/5−/10-year DSS99.5%/93.4%/80.9%/54.5%^a^Limited resection included wedge resection, segmental resection or enucleationGIST: gastrointestinal stromal tumor; NIH: National Institutes of Health; SD: standard deviation

Survival data of 202 patients with duodenal GISTs were eventually selected for analysis using exclusion criteria described in the methods section (Table [1](#Tab1){ref-type="table"}). The median follow-up time was 25.0 months (mean: 39.3 months). As shown in Fig. [1](#Fig1){ref-type="fig"}, the 1−/3−/5−/10-year DFS of duodenal GISTs was 94.4, 75.2, 64.4 and 46.5%, respectively. The 1−/3−/5−/10-year DSS was 99.5, 93.4, 80.9 and 54.5%, respectively.Fig. 1DFS and DSS of duodenal GISTs

The clinicopathological characteristics of duodenal GISTs received different surgical procedures were compared in Table [2](#Tab2){ref-type="table"}, the tumors underwent PD were mainly located in descending portion (52/77, 88.1%), and had larger diameter, higher mitotic index and higher NIH risk category (all *P* \< 0.001). Prognostic factors for duodenal GISTs according to univariate and multivariate analysis were summarized in Table [3](#Tab3){ref-type="table"}. Surgical procedure, tumor size, mitotic index and NIH risk category were risk factors for both DFS and DSS (all *P* \< 0.05). Patients underwent LR had a higher 5-year DFS (78.6% vs 35.1%, *P* \< 0.001) and DSS (83.9% vs 72.9%, *P* = 0.008) than patients underwent PD according to Kaplan-Meier analysis (Fig. [2](#Fig2){ref-type="fig"}). However, multivariate analysis showed that surgical procedure was not an independent prognostic factor (*P* \> 0.05).Table 2Comparison of clinicopathological factors of duodenal GISTs according to surgical procedureCharacteristicsLimited resection (*n* = 200)Pancreaticoduodenectomy (*n* = 77)*P* valueAge0.782  ≤ 60101 (60.5%)48 (62.3%)  \> 6066 (39.5%)29 (37.7%)Gender0.205 Male100 (51.3%)32 (42.7%) Female95 (48.7%)43 (57.3%)Anatomical location\< 0.001 Superior portion37 (19.7%)3 (5.1%) Descending portion73 (38.8%)52 (88.1%) Horizontal portion56 (29.8%)4 (6.8%) Ascending portion22 (11.7%)0Tumor size\< 0.001  ≤ 2 cm28 (15.1%)3 (4.1%) 2--5 cm102 (54.8%)25 (33.8%) 5--10 cm37 (19.9%)32 (43.2%)  \> 10 cm19 (10.2%)14 (18.9%)Mitotic index\< 0.001  ≤ 5144 (83.2%)32 (52.5%)  \> 529 (16.8%)29 (47.5%)Morphology0.146 Spindle100 (94.3%)39 (86.7%) Epithelioid01 (2.2%) Mixed6 (5.7%)5 (11.1%)NIH risk category\< 0.001 Very low23 (12.8%)2 (2.8%) Low87 (48.6%)15 (21.1%) Intermediate2 (1.1%)0 High67 (37.4%)54 (76.1%)Neoadjuvant therapy0.472 No194 (97.0%)73 (94.8%) Yes6 (3.0%)4 (5.2%)Adjuvant therapy0.362 No165 (82.5%)67 (87.0%) Yes35 (17.5%)10 (13.0%)GIST: gastrointestinal stromal tumor; NIH: National Institutes of HealthTable 3Univariate and multivariate analysis of prognostic factors for duodenal GISTsPrognostic factorsUnivariate analysisMultivariate analysisβHazard ratio (95% CI)*P* valueβHazard ratio (95% CI)*P* valueDFS Age0.4801.616 (0.874--2.987)0.126 Gender−0.1480.862 (0.470--1.582)0.632 Anatomical location0.1081.114 (0.744--1.666)0.601 Surgical procedure1.5174.559 (2.510--8.281)\< 0.001 Tumor size1.4414.224 (2.769--6.442)\< 0.0011.4064.082 (1.979--8.416)\< 0.001 Mitotic index2.0497.759 (3.751--16.048)\< 0.0011.2943.648 (1.375--9.680)0.009 NIH risk category1.4574.294 (2.394--7.702)\< 0.001 Adjuvant therapy0.3271.387 (0.514--3.742)0.518DSS Age0.3381.403 (0.596--3.300)0.438 Gender0.3241.383 (0.587--3.257)0.459 Anatomical location0.1071.113 (0.649--1.909)0.697 Surgical procedure1.0822.952 (1.274--6.837)0.012 Tumor size1.6295.100 (2.640--9.853)\< 0.0011.3393.816 (1.743--8.354)0.001 Mitotic index1.7195.580 (2.277--13.674)\< 0.001 NIH risk category1.0352.815 (1.547--5.123)0.001 Adjuvant therapy−1.3880.249 (0.033--1.877)0.178GIST: gastrointestinal stromal tumor; NIH: National Institutes of Health;DFS: disease-free survival; DSS: disease-specific survival; CI: confidence intervalFig. 2DFS and DSS of duodenal GISTs stratified by surgical procedure

Since more than half of duodenal GIST occur at the descending portion, we specifically studied the clinicopathological features of these GISTs based on the type of resection in Table [4](#Tab4){ref-type="table"}. A higher prevalence of large tumor, high mitotic index and high risk category was observed in the descending tumors received PD (all *P* \< 0.05). Univariate analysis showed that surgical procedure, tumor size, mitotic index and NIH category were risk factors for both DFS and DSS (Table [5](#Tab5){ref-type="table"}, all *P* \< 0.05). As shown in Fig. [3](#Fig3){ref-type="fig"}, LR brought a more favorable 5-year DFS (77.8% vs 48.2%, *P* = 0.002) and DSS (83.9% vs 69.3%, *P* = 0.011) than PD. However, multivariate analysis showed that surgical procedure was not an independent prognostic factor (Table [5](#Tab5){ref-type="table"}, *P* \> 0.05).Table 4Comparison of clinicopathological factors of descending duodenal GISTs according to surgical procedureCharacteristicsLimited resection (*n* = 73)Pancreaticoduodenectomy (*n* = 52)*P* valueAge0.160  ≤ 6031 (54.4%)30 (68.2%)  \> 6026 (45.6%)14 (31.8%)Gender0.976 Male27 (42.9%)22 (43.1%) Female36 (57.1%)29 (56.9%)Tumor size0.035  ≤ 2 cm12 (17.4%)2 (4.0%) 2--5 cm33 (47.8%)19 (38.0%) 5--10 cm17 (24.6%)20 (40.0%)  \> 10 cm7 (10.1%)9 (18.0%)Mitotic index\< 0.001  ≤ 550 (86.2%)25 (54.3%)  \> 58 (13.8%)21 (45.7%)Morphology0.165 Spindle35 (97.2%)27 (84.4%) Epithelioid01 (3.1%) Mixed1 (2.8%)4 (12.5%)NIH risk category0.001 Very low10 (15.4%)1 (2.1%) Low28 (43.1%)11 (22.9%) Intermediate00 High27 (41.5%)36 (75.0%)Neoadjuvant therapy0.401 No69 (94.5%)51 (98.1%) Yes4 (5.5%)1 (1.9%)Adjuvant therapy0.777 No33 (80.5%)30 (83.3%) Yes8 (19.5%)6 (16.7%)GIST: gastrointestinal stromal tumor; NIH: National Institutes of HealthTable 5Univariate and multivariate analysis of prognostic factors for the descending duodenal GISTsPrognostic factorsUnivariate analysisMultivariate analysisβHazard ratio (95% CI)*P* valueβHazard ratio (95% CI)*P* valueDFS Age0.4871.628 (0.632--4.193)0.313 Gender−0.3750.687 (0.279--1.694)0.415 Surgical procedure1.4734.361 (1.597--11.909)0.004 Tumor size1.4454.240 (2.073--8.672)\< 0.0011.7215.590 (2.144--14.570)\< 0.001 Mitotic index1.6965.453 (2.065--14.400)0.001 NIH risk category1.4564.288 (1.594--11.531)0.004 Adjuvant therapy0.5441.724 (0.367--8.103)0.491DSS Age0.2761.318 (0.432--4.019)0.627 Gender0.0081.008 (0.316--3.218)0.989 Surgical procedure1.5194.569 (1.260--16.569)0.021 Tumor size2.1428.515 (2.496--29.053)0.0011.9767.213 (2.138--24.338)0.001 Mitotic index1.5674.792 (1.428--16.087)0.011 NIH risk category1.1433.136 (1.150--8.552)0.026 Adjuvant therapy−3.1810.042 (0.000--212.916)0.465GIST: gastrointestinal stromal tumor; NIH: National Institutes of Health;DFS: disease-free survival; DSS: disease-specific survival; CI: confidence intervalFig. 3DFS and DSS of descending duodenal GISTs stratified by surgical procedure

The clinicopathological characteristics of 300 duodenal GISTs including age, gender, tumor size, mitotic index, morphology and NIH risk category were compared with 378 gastric GISTs from out center (Table [6](#Tab6){ref-type="table"}). The tumor size, mitotic index and NIH risk category were significantly different between the two groups (all *P* \< 0.001).Table 6Comparison of clinicopathological characteristics between duodenal and gastric GISTsCharacteristicsDuodenum (*n* = 300)Stomach (*n* = 378)*P* valueAge0.791  ≤ 60161 (60.3%)224 (59.3%)  \> 60106 (39.7%)154 (40.7%)Gender0.826 Male143 (49.1%)189 (50.0%) Female148 (50.9%)189 (50.0%)Tumor size\< 0.001  ≤ 2 cm34 (12.3%)126 (33.5%) 2--5 cm135 (48.7%)138 (36.7%) 5--10 cm73 (26.4%)86 (22.9%)  \> 10 cm35 (12.6%)26 (6.9%)Mitotic index\< 0.001  ≤ 5181 (75.4%)225 (61.1%)  \> 559 (24.6%)143 (38.9%)Morphology0.825 Spindle148 (92.5%)341 (93.9%) Epithelioid1 (0.6%)2 (0.6%) Mixed11 (6.9%)20 (5.5%)NIH risk category\< 0.001 Very low25 (9.7%)105 (28.5%) Low104 (40.3%)97 (26.3%) Intermediate2 (0.8%)87 (23.6%) High127 (49.2%)80 (21.7%)GIST: gastrointestinal stromal tumor; NIH: National Institutes of Health

In order to analyze the prognosis of duodenal and gastric GISTs, survivals of 202 duodenal GISTs were compared to those of 253 gastric GISTs according to the exclusion criteria of survival analysis. The univariate and multivariate analysis showed that location was an independent risk factor for DFS and DSS (*P* \< 0.001, Table [7](#Tab7){ref-type="table"}). As shown in Fig. [4](#Fig4){ref-type="fig"}, the 5-year DFS (64.4% vs 94.9%, *P* \< 0.001) and DSS (80.9% vs 92.6%, *P* = 0.049) of duodenal GISTs were significantly worse than that of gastric GISTs.Table 7Univariate and multivariate analysis of prognostic factors for duodenal and gastric GISTsPrognostic factorsUnivariate analysisMultivariate analysisβHazard ratio (95% CI)*P* valueβHazard ratio (95% CI)*P* valueDFS Age−0.0840.920 (0.517--1.638)0.776 Gender−0.3930.675 (0.384--1.186)0.172 Location−2.1050.122 (0.057--0.259)0.000−2.1220.120 (0.054--0.266)\< 0.001 Tumor size1.4514.268 (2.932--6.213)0.0001.4174.124 (2.526--6.733)\< 0.001 Mitotic index1.2833.608 (1.868--6.970)0.0000.9282.528 (1.225--5.219)0.012 NIH risk category1.8136.128 (3.254--11.544)0.000DSS Age0.3871.473 (0.748--2.898)0.2630.7592.136 (1.040--4.384)0.039 Gender0.2791.322 (0.668--2.614)0.423 Location−0.7180.488 (0.236--1.010)0.049−1.0660.344 (0.164--0.725)0.005 Tumor size1.2973.658 (2.304--5.807)0.0001.3863.999 (2.408--6.641)\< 0.001 Mitotic index1.2023.327 (1.574--7.032)0.002 NIH risk category1.0942.985 (1.821--4.895)0.000GIST: gastrointestinal stromal tumor; NIH: National Institutes of Health;DFS: disease-free survival; DSS: disease-specific survival; CI: confidence intervalFig. 4Comparison of DFS and DSS between duodenal and gastric GISTs

Discussion {#Sec4}
==========

The current study represented the largest number of duodenal GISTs to date. We found that LR was a more prevalent surgical procedure and PD was mainly performed for tumors with larger diameter or located in descending portion. Type of resection was not an independent risk factor for the prognosis of duodenal GISTs. Prognosis of duodenal GISTs was significantly worse than that of gastric GISTs.

GISTs are thought to derive from the interstitial cells of Cajal (ICC) \[[@CR114]\], the pacemaker cells of gastrointestinal tract \[[@CR115], [@CR116]\]. A recent study found that the type of ICC distributed in proximal duodenum is very similar to that in stomach, and its distal duodenal pattern is more identical to that in jejunoileum \[[@CR117]\]. Moreover, they found that ICC of circular muscle are only distributed in the proximal duodenum and are absent in the distal portion. In our study, most tumors located in the proximal portion of duodenum (superior and descending portion), which was consistent with the previous literature \[[@CR1], [@CR9], [@CR13], [@CR118]\]. This distribution characteristics may attribute to the distribution of ICC in this region. However, this remains to be further investigated.

Surgical strategy of duodenal GISTs remains challenging, owing to the unique anatomy of duodenum \[[@CR91]\]. Complete surgical resection with sufficient margin and without intraoperative tumor rupture remains as the curative treatment for GISTs \[[@CR2], [@CR119]\]. Tumor size, location and invasion of adjacent organs are generally considered for the choice of surgery for duodenal GISTs \[[@CR13], [@CR120]\]. A few studies proponing PD as a routine procedure argued that an extensive surgery is always required in the pancreaticoduodenal region to obtain a clear margin and achieve a good oncological outcome \[[@CR7], [@CR13], [@CR121]\]. On the other hand, LR, a less demanding procedure, could obviously decrease the perioperative morbidity and brings a parallel \[[@CR121], [@CR122]\] or better survival compared with PD \[[@CR14]\]. A meta-analysis suggested LR as the routine choice for the duodenal GISTs whenever technically feasible, due to the good oncological outcomes and lower morbidity brought by this procedure compared with PD \[[@CR118]\]. However, these results were all based on small samples. In our study, PD was mainly performed for GISTs with larger tumor size, higher risk-category or arose from descending portion. Although PD was associated with poorer survival of patients, surgical procedure was not an independent prognostic factor for duodenal GISTs. The survival disadvantage of PD observed in our study may be due to the higher-risk tumors distributed in the PD group.

In fact, the argument about LR and PD for duodenal GISTs mainly focused on tumors located in the descending portion. To date, study focused on this issue is lacking. In our study, PD was mainly performed for the descending GISTs. And, due to the particularly anatomic features of the duodenal descending portion, we then investigated the survival impact of surgical procedure for this subgroup of GISTs. The results showed that patients with descending GISTs underwent PD had larger tumor size and poorer DFS and DSS than those of patients underwent LR. However, multivariate analysis revealed that surgical procedure was not an independent prognostic factor.

Although our study indicated that type of resection was not associated with the prognosis of duodenal GISTs, the conclusion should be interpreted cautiously. For example, PD was the only choice to achieve a clearance margin when tumors were too large or close to the anatomically disadvantageous region. Thus, it is meaningless to compare the clinical impact of different types of resection without consideration of size and location of tumor. These two procedures could be compared only when the tumor is not large enough and is distant from the critical structures. However, to date, there is no more detailed study published. It is also a limitation in our study that the information of tumor location and involvement of the pancreaticoduodenal complex could not be extracted from published literatures.

Beside tumor size and mitotic index, tumor location is also reported as a key prognostic factor for GISTs \[[@CR123], [@CR124]\]. There are three main risk-stratification methods used to estimate the prognosis of GIST after surgery: NIH consensus criteria \[[@CR125]\], Armed Forces Institute of Pathology (AFIP) criteria \[[@CR126]\] and modified NIH criteria \[[@CR113]\]. The latter two both include tumor site but only the AFIP criteria stratifies site into stomach, duodenum, jejunum and rectum while the modified NIH criteria only encompasses stomach and non-stomach. Even though, the comparison of survival between duodenal GISTs and GISTs from other sites was still rare due to the extremely low incidence \[[@CR65]\]. Thus, we compared the prognosis of duodenal GISTs to gastric GISTs from our center. The univariate and multivariate analysis revealed that the DFS and DSS of duodenal were significantly worse than those of gastric GISTs. However, a recently nation-wide study \[[@CR127]\] extracting GIST cases from Surveillance, Epidemiology, and End Results (SEER) database showed that gastric and small intestine GISTs had similar outcomes. This contrary result might because duodenal GIST was not analyzed separately from the small intestine GIST in their study which could lead to a bias. Actually, there is also a deficiency in current study, that the number of gastric GISTs in our study was relatively small compared to the large number of duodenal GISTs.

There are some other limitations in current study. Firstly, it is a retrospective single-center study and the completeness of systematic data is limited. Till now, the survival impact of surgical procedure on duodenal GISTs is still controversial, mainly because the lack of more accurate description of location of tumors in previous studies, which could result in a bias. Although the current study contained the largest number of duodenal GISTs, it still failed to make up this deficiency. Thus, a multi-center randomized control trial is needed to clarify this question. Secondly, due to the small size of small intestinal and colorectal GISTs in our center, the prognosis of duodenal GISTs were only compared to that of gastric GISTs.

Conclusions {#Sec5}
===========

The most common symptom of duodenal GISTs was bleeding. Descending portion was the most frequent tumor site. LR was a more prevalent surgical procedure and PD was mainly performed for tumors with larger diameter or located in descending portion. But type of resection was not an independent risk factor for the prognosis of duodenal GISTs. Thus, the choice of surgical strategy of duodenal GISTs prevalently depended on tumor size and location. Prognosis of duodenal GISTs was significantly worse than that of gastric GISTs.
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DFS

:   Disease-free survival

DSS

:   Disease-specific survival

GISTs

:   Gastrointestinal stromal tumors

ICC

:   Interstitial Cajal cells

LR

:   Limited resection

PD

:   Pancreaticoduodenectomy

SEER

:   Surveillance, Epidemiology, and End Results

**Electronic supplementary material**

The online version of this article (10.1186/s12885-018-4485-4) contains supplementary material, which is available to authorized users.

We wish to thank Xingbin Hu for his help with the revision of manuscript.

Funding {#FPar1}
=======

This study was supported in part by grants from the National Natural Scientific Foundation of China \[NO. 31100643, 31570907, 81572306, 81502403, XJZT12Z03\]. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing of this manuscript.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

ZL, GZZ and JQL conceived the study and drafted the manuscript. SSL, GHX and QW collected the data and participated in drafting the manuscript. MG and XL performed statistical analysis. HWZ designed and supervised the study. All authors read and approved the final manuscript. All authors contributed to the writing of the manuscript and provided final approval of the manuscript. All authors have read and approved the final version of this manuscript. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved by the Ethics Committee of Xijing Hospital, and written informed consent was obtained from the patients in our center.

Competing interests {#FPar4}
===================

There are no financial or other relations that could lead to a conflict of interest.

Publisher's Note {#FPar5}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
